Shares of Amneal Pharmaceuticals (NASDAQ:AMRX) rose 10% on Monday after J.P. Morgan raised its rating on the stock to overweight from neutral, based on in part on the launch of the drug Crexont. In a ...
Amneal announced FDA acceptance of its Biologics License Application (BLA) for two proposed denosumab biosimilars ...
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global biopharmaceutical company. We make healthy possible through the development, manufacturing, and distribution ...
The Federal Circuit’s refusal to reconsider its ruling forcing Teva to delist asthma-inhaler patents from the FDA’s Orange ...
Amneal Pharmaceuticals (NYSE:NASDAQ:AMRX), a commercial-stage biopharmaceutical company with a market capitalization of $2.74 billion, has been making significant strides in the pharmaceutical ...
Barclays raised the firm’s price target on Amneal Pharmaceuticals (AMRX) to $11 from $10 and keeps an Overweight rating on the shares. The ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amneal Pharmaceuticals (AMRX – Research Report), Sandoz ...
On Wednesday, 12 March 2025, Amneal Pharmaceuticals (NASDAQ: AMRX) participated in the Barclays 27th Annual Global Healthcare Conference 2025, where Chairman and CEO Chirag Patel outlined the ...
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) will present at the Barclays 27th Annual Global Healthcare Conference on March, 12, 2025. Chirag Patel, Co-Chief Executive Officer and President ...
Amneal Pharmaceuticals (NYSE:NASDAQ:AMRX), a commercial-stage biopharmaceutical company with a market capitalization of $2.74 billion, has been making significant strides in the pharmaceutical ...
The FDA has accepted Amneal’s biologics licensing application for two biosimilars referencing Prolia and Xgeva.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback